Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 6/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.36 |
| ▸ | FEN1 | P39748 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12653110 | 0.95 | KDM1A (0.37) | KDM1ABRD4TRPV1ALOX5APFEN1 | |
| SCHEMBL2937391 | 0.93 | KDM1A (0.45) | KDM1ABRD4TRPV1ALOX5APFEN1 | |
| SCHEMBL1794967 | 0.92 | KDM1A (0.51) | KDM1ABRD4TRPV1ALOX5APFEN1 | |
| SCHEMBL1798976 | 0.88 | KDM1A (0.43) | KDM1ABRD4TRPV1ALOX5APFEN1 | |
| SCHEMBL1799974 | 0.87 | KDM1A (0.46) | KDM1ABRD4TRPV1ALOX5APFEN1 | |
| SCHEMBL12350194 | 0.85 | TRPV1 (0.52) | KDM1ABRD4TRPV1ALOX5APFEN1 | |
| SCHEMBL1798578 | 0.84 | KDM1A (0.50) | KDM1ABRD4TRPV1ALOX5APFEN1 | |
| SCHEMBL1796485 | 0.84 | TRPV1 (0.52) | KDM1ABRD4TRPV1ALOX5APFEN1 | |
| SCHEMBL1800456 | 0.84 | TRPV1 (0.54) | KDM1ABRD4TRPV1ALOX5APFEN1 | |
| SCHEMBL1799444 | 0.84 | KDM1A (0.42) | KDM1ABRD4TRPV1ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190364-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
| US-7951829-B2 | Benzimidazole modulators of VR1 | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190364-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | KDM1A 1102/4885BRD4 405/4885TRPV1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.